The search methodology followed a narrative, evidence-integrated review design focused on evaluating olezarsen, an antisense inhibitor of ApoC-III, in the management of FCS and severe hypertriglyceridemia. This evidence concerns the gene APOC3 and hypertriglyceridemia.